These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28370242)

  • 41. Compliance with iron-chelation treatment after bone marrow transplantation.
    Vreugdenhil G; Smeets M; Broekhuysen AM
    Lancet; 1994 Mar; 343(8897):604. PubMed ID: 7906360
    [No Abstract]   [Full Text] [Related]  

  • 42. Health-related quality of life in Thai thalassemic children treated with iron chelation.
    Torcharus K; Pankaew T
    Southeast Asian J Trop Med Public Health; 2011 Jul; 42(4):951-9. PubMed ID: 22299478
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
    Peng CT; Tsai CH; Wu KH
    Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral iron chelators.
    Nathan DG; Piomelli S
    Semin Hematol; 1990 Apr; 27(2):83-5. PubMed ID: 2190320
    [No Abstract]   [Full Text] [Related]  

  • 45. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quality of life in thalassemia.
    Telfer P; Constantinidou G; Andreou P; Christou S; Modell B; Angastiniotis M
    Ann N Y Acad Sci; 2005; 1054():273-82. PubMed ID: 16339675
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES; Karasmanis K; Perifanis V; Vlachaki E; Tziomalos K; Economou M
    Hemoglobin; 2014; 38(2):111-4. PubMed ID: 24351163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
    Payne KA; Rofail D; Baladi JF; Viala M; Abetz L; Desrosiers MP; Lordan N; Ishak K; Proskorovsky I
    Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T2* magnetic resonance and myocardial iron in thalassemia.
    Pennell DJ
    Ann N Y Acad Sci; 2005; 1054():373-8. PubMed ID: 16339685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bull's eye maculopathy with deferoxamine.
    Bansal V; Elgarbly I; Ghanchi FD; Atkinson PL
    Eur J Haematol; 2003 Jun; 70(6):420-1. PubMed ID: 12756028
    [No Abstract]   [Full Text] [Related]  

  • 54. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Medical management of beta-thalassemia.
    Lerner N
    Prog Clin Biol Res; 1989; 309():13-22. PubMed ID: 2780747
    [No Abstract]   [Full Text] [Related]  

  • 57. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
    Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical Management of Patients With Thalassemia Syndromes.
    Martin M; Haines D
    Clin J Oncol Nurs; 2016 Jun; 20(3):310-7. PubMed ID: 27206298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review.
    Evangeli M; Mughal K; Porter JB
    Hemoglobin; 2010 Jun; 34(3):305-21. PubMed ID: 20524820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FDA panel recommends approval of deferiprone.
    Shuchman M
    CMAJ; 2011 Nov; 183(16):E1159-60. PubMed ID: 21948726
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.